Pharma News, 2024

BlossomHill Therapeutics has secured $100m in a Series B financing round, a significant move to progress the development of its programmes targeting cancer and autoimmune diseases.

Food makers can advertise that regularly eating yogurt may reduce the risk of Type 2 diabetes without objection from the Food and Drug Administration, the agency announced on Friday.

The Food and Drug Administration approved Rybrevant plus carboplatin and pemetrexed for locally advanced or metastatic non-small cell lung cancer (NSCLC) that has EGFR exon 20 insertion mutations.

The FDA has issued a Complete Response Letter for the New Drug Application of cefepime-taniborbactam, requesting additional chemistry, manufacturing, and controls data.

Biotechnology company Ocugen announced that dosing is complete in the first cohort of its phase 1/2 GARDian clinical trial of OCU410ST, a modifier gene therapy candidate for treatment of Stargardt...

AbbVie and Tentarix Biotherapeutics have announced a multi-year collaboration aimed at developing biologic candidates in oncology and immunology.

The FDA's Office of Generic Drugs reported a rise in generic drug approvals, as several first-time generics entered the market.

American Hospital Association or AHA urged healthcare facilities across the United States to disconnect from Change Healthcare.

Researchers from the US have discovered more than 275 million genetic variants identified through the National Institutes of Health’s (NIH) All of Us Research Program. ...

A Phase I trial studying the therapy is underway after an FDA clinical hold was lifted last year, with initial data expected in 2024.

The immune-mediated inflammatory bowel disease affects approximately 2.6 million people in Europe.

All patients in a trial have been offered the long-acting drug. Drugmaker is betting on injectable treatments for HIV.